非典型抗精神病药物的药物经济学

Study on Pharmacoeconomics of Atypical Antipsychotic Drugs

目的探讨非典型抗精神病药物的药物经济学。方法选择本院2015年6月至2017年6月收治的接受单一非典型抗精神病药物治疗的157例患者为研究对象,根据不同的治疗药物分为利培酮组(52例)、齐拉西酮组(54例)、奥氮平组(51例),观察3组用药效果、治疗成本效果及不良反应发生情况。结果利培酮组治疗有效率为90.38%、齐拉西酮组为92.59%、奥氮平组为92.20%,组间差异均无统计学意义(P>0.05);利培酮组成本-效果最小,齐拉西酮组次之,奥氮平组最大;利培酮组药物不良反应率为36.54%,奥氮平组为27.45%,齐拉西酮为14.81%。结论非典型抗精神病药物中以利培酮最具经济性,其次为齐拉西酮,最后为奥氮平,3种药物均可获得良好的疗效,不良反应少,安全性高。

Objective To explore the pharmacoeconomics of atypical antipsychotic drugs.Methods A total of 157 patients who received single atypical antipsychotic treatment in our hospital from June 2015 to June 2017 were selected as the research objects.According to different treatment drugs,they were divided into risperidone group(52 cases)and ziprasidone group(54 cases),olanzapine group(51 cases).Three groups of medication effects,treatment cost effects and adverse reactions were observed.Results The effective rate of treatment in the risperidone group was 90.38%,the ziprasidone group was 92.59%,and the olanzapine group was 92.20%.There was no statistically significant difference between the groups(P>0.05).The risperidone component had the least effect,ziprasidone group followed,olanzapine group was the largest;the adverse drug reaction rate of risperidone group was 36.54%,olanzapine group was 27.45%,and ziprasidone was 14.81%.Conclusion In the use of atypical antipsychotics,the most economical benefit for risperidone,and the second is ziprasidone,and the last is olanzapine,and it can achieve good curative effect,few adverse reactions and high safety.